No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

6/2

Benz Sciences

Taiho

Pharmaceutical

SFG-03
(TAS1440)

LSD1 Inhibitor

Oncology

AML

Preclinical

n/d

2

6/2

Regeneron

Hansoh Pharma

Olatorepatide

(HS-20094)

GLP-1R x GIPR dual agonist

Metabolic

disorder

Obesity

Phase 3

2,000

3

6/2

BMS

BioNTech

BNT327

αPD-1/L1xVEGF-A BsAb

Oncology

TNBC

Phase 3

11,100

4

6/3

Eli Lilly

Camurus

FluidCrystal®

Technology to develop long-acting

incretin products

Metabolic

disorder

Obesity, Diabetes

-

870

5

6/3

Alto

Neuroscience

Chase

Therapeutics

ALTO-207
(CTC-501)

Dopamine D3-preferring D3 / D2

agonist, 5-HT3 receptor

antagonist

Neurology

Resistant depression

Phase 2

71.5

6

6/3

Kiora Pharma

Senju Pharma

KIO-301

DHODH inhibitor

Ophthalmology

Inherited retinal diseases

Phase 2

110

7

6/3

Transpire Bio

Suzhou

Intragrand

Pharma

Lenamilast

(ITG-1052)

PDE4 inhibitor

Respiratory

diseases

Idiopathic pulmonary fibrosis

Preclinical

n/d

8

6/4

Vividion

Therapeutics

(Bayer)

Roche

VVD-214
(RO7589831)

WRN inhibitor

Oncology

Solid tumors

Phase 1

n/d

9

6/4

Allarity

Therapeutics

Indiana

Biosciences

Research

Institute

Stenoparib

PARP-1/2, TNKS1/2 inhibitor

Oncology

Advanced ovarian cancer, SCLC

Phase 2

n/d

10

6/4

Cullinan

Therapeutics

Genrix Bio

Velinotamig

αCD3xBCMA BsAb

Immunology

Autoimmune diseases

Preclinical

712

11

6/5

LigaChemBio

NovaRock

Biotherapeutics

n/d

ADC

Oncology

Solid tumors (Lung, Colorectal,

Gastric, Pancreatic)

n/d

n/d

12

6/5

n/d

Ocugen

OCU400

NR2E3-targeting gene therapy

Ophthalmology

Retinitis pigmentosa

Phase 3

11

13

6/9

SOLVE FSHD

Modalis

Therapeutics

MDL-1039433

DUX4-targeting gene therapy

Neuromuscular

diseases

Facioscapulohumeral

Muscular Dystrophy

Preclinical

n/d

14

6/9

SK Plasma

AimedBio

n/d

ROR1-targeting ADC

Oncology

Solid tumors

Preclinical

n/d

15

6/9

BeOne

Medicines

Neowise

Biotechnology

n/d

TCR-T cell therapies

Oncology

Solid tumors

n/d

n/d

16

6/10

Acino
(Arcera)

AriBio

AR1001

PDE-5 inhibitor

Neurology

Alzheimer’s disease

Phase 3

600

17

6/10

Biohaven

Bexorg

BrainEx
XO Digital

Whole-brain discovery platform

AI engine

Neurology

-

-

n/d

18

6/10

RayzeBio
(BMS)

Philochem AG

OncoACP3

ACP3-targeting RPT

Oncology

Prostate Cancer

Preclinical

1,350

19

6/11

Chiesi Farmaceutici

Key2Brain

n/d

BBB-crossing ERTs

Neurology

Lysosomal storage disorders;
α-mannosidosis, Krabbe disease

Preclinical

n/d

20

6/11

Eli Lilly

Juvena Therapeutics

JuvNET

AI enabled screening platform

Musculoskeletal diseases

Losing lean mass

Preclinical

650

21

6/11

Novo Nordisk

Deep Apple
 Therapeutics

n/d

Non-incretin GPCR targeting oral

small molecule

Cardio-

metabolic

disease

Cardiometabolic diseases including

obesity

Preclinical

812

22

6/11

Daewoong

Pharmaceutical

Salipro Biotech

Salipro®

Technology designed to stabilize

membrane proteins

-

-

-

n/d

23

6/13

AstraZeneca

CSPC

Pharmaceuticals

YS2302018

Lp(a) disruptor

Metabolic

disorder

Dyslipidemia

Preclinical

5,320

24

6/16

NextCure

Simcere

Zaiming Pharma

SIM0505

CDH6-targeting ADC

Oncology

Solid tumors

Phase 1

745

25

6/16

Pierre Fabre

Laboratories

Antares

 Therapeutics

PFL-721

PFL-241

Mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor

Mutant-specific, brain penetrant, 4th generation EGFR inhibitor

Oncology

NSCLC

NSCLC

Preclinical

Preclinical

177

26

6/16

Shanghai

Escugen

Biotechnology

SunRock

 Biopharma

SRB123

CCR9-targeting ADC

Oncology

Solid tumors

Preclinical

n/d

27

6/16

Fosun Pharma

Teva

TEV-56278

αPD1-IL2 ATTENUKINETM therapy

Oncology

Solid tumors; melanoma

Phase 1

n/d

28

6/17

Intact

Therapeutics

Processa

Pharmaceuticals

PCS12852

5-HT4 receptor agonist

Gastrointestinal diseases

Gastroparesis,

Other gastrointestinal motility

disorders.

Phase 2

452.5

29

6/18

Oceanus Bio

Avata

Biosciences

Holdings

AVAT-021

AVAT-022

Cannabinoid receptors agonist

Cannabinoid receptors agonist

Neurology

Neurology

Schizophrenia

Epilepsy

Phase 1

Preclinical

95

30

6/18

Synfini Inc.

O2nix Bio

n/d

FTSJ1-targeting tRNA therapeutics

Oncology

Cancer

Preclinical

n/d

31

6/23

Otsuka

Pharmaceutical

Harbour

BioMed

HBM7020

BCMAxCD3 bispecific T-cell

engagers

Immunology

Autoimmune diseases

Phase 1

670

32

6/23

Chuang Yi

Global Asset

 Management

Denovo

Biopharma LLC

Liafensine

(DB104)

SNDRI

Neurology

Treatment-Resistant Depression

Phase 2

n/d

33

6/23

Ono

Pharmaceutical

Vertex

Povetacicept

APRIL x BAFF dual antagonists

Genitourinary

diseases

IgA nephropathy

Phase 3

n/d

34

6/23

Sanofi

Libertas Bio
(Formation Bio)

Gusacitinib

JAK x SYK dual inhibitor

Dermatology

Dermatitis

Phase 2

629.3

35

6/24

ABION Bio

n/d

ABN501

αCLDN mAb

Oncology

Solid tumors; Small cell lung cancer, Breast cancer, Ovarian cancer

Preclinical

1,300

36

6/25

Cyntec
(OEP)

Rakuten Medical

Alluminox™

IR700 dye-conjugated, light-

activatable, target-specific

photoimmunotherapy

Oncology

Head and neck cancer

-

n/d

37

6/25

Gilead Sciences

Kymera

Therapeutics

n/d

CDK2 targeting molecular glue

degrader

Oncology

Solid cancer; Breast cancer

-

750

38

6/26

Vor Bio

RemeGen

Telitacicept

BAFF x APRIL dual inhibitor

Immunology

Autoimmune diseases;
systemic lupus erythematosus,
Generalized myasthenia gravis,
Rheumatoid arthritis

Marketed

Marketed

Phase 3

4,230

39

6/26

Calico

Life Sciences
(Alphabet)

Mabwell

Bioscience

9MW3811

αIL-11 mAb

Respiratory

diseases

Oncology

Idiopathic Pulmonary Fibrosis

Advanced Malignant Solid

Neoplasm

Phase 1

Phase 1

596

40

6/26

Percheron Therapeutics

Hummingbird Bioscience

HMBD-002

αVISTA mAb

Oncology

Solid tumors

Phase 1/2

n/d

41

6/26

Novartis

ProFound

Therapeutics

ProFoundryTM

Protein detection platform

Cardiovascular

diseases

n/d

n/d

750

42

6/30

Curadh MTR

Alpha Fusion

At-211

Astatine-211 based RPT

Oncology

n/d

n/d

n/d

43

6/30

Summit Therapeutics

Revolution

Medicines

Daraxonrasib
(RMC-6236)

​Zoldonrasib
(RMC-9805)

Elironrasib (RMC-6291)

Multi-selective RAS inhibitor

G12D-selective inhibitor

G12C-selective inhibitor

Oncology

Oncology

Oncology

NSCLC, Pancreatic cancer

RAS mut. NSCLC

Unspecified cancer;

colorectal cancer

Phase 3

Phase 1/2

Preclinical

n/d

44

6/30

Shanghai

Henlius Biotech

FBD Biologics
(HanchorBio)

HCB101

CD47/SIRPα inhibitor 

Oncology

Solid tumors; Head and neck,

Gastric, Colorectal and Breast

cancers

Phase 2

202

45

6/30

LG chem

SPARK

Biopharma

PhenoCure+

pDOS Library Screening for PPI

Inhibition

n/d

-

-

n/d

46

6/30

Pfizer

XtalPi

XFEP/XFF

AI-driven small molecular

modeling platform

n/d

-

-

n/d

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

6/2

Sanofi

Blueprint Medicines

Ayvakit
(Avapritinib)
Elenestinib

BLU-808

c-KIT, PDGFRA inhibitor

KIT D816V

Wild type c-KIT

Oncology

Immunology

Immunology

Immunology

GIST,
Indolent systemic mastocytosis

Indolent systemic mastocytosis

Chronic urticaria

Marketed

Phase2/3

Phase2

9,500

2

6/4

Continuity Biosciences

Focal Medical

Iontophoresis platform

Drug delivery system

Oncology

Pancreatic cancer

-

n/d

3

6/5

Juvenescence

Ro5

AI drug

Discovery

platform

DL-based affinity and pose prediction for target ID and compound prioritization

Cardio-metabolic disease,  etc.

Cognition, cardio-metabolism, immunity, cellular repair

-

76

4

6/9

Concentra Biosciences

Elevation Oncology

EO-1022

HER3 targeting ADC

Oncology

Solid tumors

Preclinical

21.4

5

6/12

BioNTech

CureVac

CVGBM

mRNA vaccine

Oncology

Glioblastoma

Phase 1

1,250

6

6/16

Supernus Pharmaceutical

Sage Therapeutics

Zurzuvae
(Zuranolone)

GABA A receptor modulator

Neurology

Depression

Marketed

561

7

6/18

Eli Lilly

Verve Therapeutics

VERVE-102

Inactivating the PCSK9 gene in the liver

Cardiovascular disease

Atherosclerosis

Phase 1

1,300

8

6/25

Launch One Acquisition Corp.

Minovia Therapeutics Ltd.

MNV-201

Hematopoietic stem cell therapy

Metabolic disorder

Mitochondrial dysfunction;
 VLCAD Deficiency, Kearn-Sayre     
 Syndrome

Phase 2

180

9

6/25

Novartis

Regulus Therapeutics

Farabursen

miR-17 targeting ASO

Genitourinary diseases

Autosomal dominant polycystic kidney disease

Phase 1

394.62

9

6/27

Xoma Royalty

Turnstone Biologics

n/d

Selected tumor - infiltrating lymphocyte technologies

Oncology

Solid tumor

n/d

8

10

6/30

AbbVie

Capstan Therapeutics

CPTX2309

tLNP anti-CD19 CAR-T

Immunology

Autoimmune diseases

Phase 1

2,100

11

6/30

Oncoinvent

BerGenBio

Radspherin

224Ra α-RPT

Oncology

Peritoneal carcinomatosis

Phase 1/2

43.3